Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2021

Open Access 01-12-2021 | Fabry Disease | Research

Retinal vessel tortuosity as a prognostic marker for disease severity in Fabry disease

Authors: Yevgeniya Atiskova, Jan Wildner, Martin Stephan Spitzer, Charlotte Aries, Nicole Muschol, Simon Dulz

Published in: Orphanet Journal of Rare Diseases | Issue 1/2021

Login to get access

Abstract

Purpose

The aim of this case control study was to evaluate the prognostic value of automatically quantified retinal vessel tortuosity from fundus images and vessel density from OCT-A in Fabry disease and to evaluate the correlation of these with systemic disease parameters.

Methods

Automatically quantified perimacular retinal vessel tortuosity (MONA REVA software), acquired by fundus imaging, and perifoveal retinal vessel density, acquired by optic coherence tomography angiography (OCT-A) were compared between 26 FD patients and 26 controls. Gender and FD phenotype were analyzed to the obtained retinovascular data and correlated to the Mainz severity score index (MSSI) and plasma lyso-Gb3.

Results

Automatically quantified retinal vessel tortuosity indices of FD patients were significantly lower, reflecting an increased vessel tortuosity, compared to controls (p = 0.008). Males with a classical phenotype showed significantly lower retinal vessel tortuosity indices compared to males with an oligosymptomatic phenotype and females with a classical or oligosymptomatic phenotype (p < 0.001). The retinal vessel tortuosity index correlated significantly with systemic disease severity parameters [global MSSI (r = − 0.5; p < 0.01), cardiovascular MSSI (r = − 0.5; p < 0.01), lyso-Gb3 (r = − 0.6; p < 0.01)].

Conclusion

We advocate fundus imaging based automatically quantified retinal vessel tortuosity index over OCT-A imaging as it is a quick, non-invasive, easily assessable, objective and reproducible marker.
Literature
1.
go back to reference Desnick RJ, Dean KJ, Grabowski GA, et al. Enzyme therapy XVII: metabolic and immunologic evaluation of alpha-galactosidase A replacement in Fabry disease. Birth Defects Orig Artic Ser. 1980;16:393–413.PubMed Desnick RJ, Dean KJ, Grabowski GA, et al. Enzyme therapy XVII: metabolic and immunologic evaluation of alpha-galactosidase A replacement in Fabry disease. Birth Defects Orig Artic Ser. 1980;16:393–413.PubMed
2.
go back to reference El-Abassi R, Singhal D, England JD. Fabry’s disease. J Neurol Sci. 2014;344:5–19.CrossRef El-Abassi R, Singhal D, England JD. Fabry’s disease. J Neurol Sci. 2014;344:5–19.CrossRef
3.
go back to reference Sakuraba H, Oshima A, Fukuhara Y, et al. Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet. 1990;47:784–9.PubMedPubMedCentral Sakuraba H, Oshima A, Fukuhara Y, et al. Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet. 1990;47:784–9.PubMedPubMedCentral
5.
go back to reference Anderson-Fabry disease. Lancet 1990;336:24–5. Anderson-Fabry disease. Lancet 1990;336:24–5.
6.
go back to reference Hopkin RJ, Bissler J, Banikazemi M, et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res. 2008;64:550–5.CrossRef Hopkin RJ, Bissler J, Banikazemi M, et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res. 2008;64:550–5.CrossRef
7.
go back to reference Schaefer E, Mehta A, Gal A. Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey. Acta Paediatr Suppl. 2005;94:87–92 (discussion79).CrossRef Schaefer E, Mehta A, Gal A. Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey. Acta Paediatr Suppl. 2005;94:87–92 (discussion79).CrossRef
8.
go back to reference Kramer J, Weidemann F. Biomarkers for diagnosing and staging of Fabry disease. Curr Med Chem. 2018;25:1530–7.CrossRef Kramer J, Weidemann F. Biomarkers for diagnosing and staging of Fabry disease. Curr Med Chem. 2018;25:1530–7.CrossRef
9.
go back to reference Whybra C, Kampmann C, Krummenauer F, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet. 2004;65:299–307.CrossRef Whybra C, Kampmann C, Krummenauer F, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet. 2004;65:299–307.CrossRef
10.
go back to reference Peters H, Ellaway C, Nicholls K, et al. Treatable lysosomal storage diseases in the advent of disease-specific therapy. Intern Med J. 2020;50(Suppl 4):5–27.CrossRef Peters H, Ellaway C, Nicholls K, et al. Treatable lysosomal storage diseases in the advent of disease-specific therapy. Intern Med J. 2020;50(Suppl 4):5–27.CrossRef
11.
go back to reference van der Veen SJ, Hollak CEM, van Kuilenburg ABP, Langeveld M. Developments in the treatment of Fabry disease. J Inherit Metab Dis. 2020;43:908–21.CrossRef van der Veen SJ, Hollak CEM, van Kuilenburg ABP, Langeveld M. Developments in the treatment of Fabry disease. J Inherit Metab Dis. 2020;43:908–21.CrossRef
12.
go back to reference Pitz S, Kalkum G, Arash L, et al. Ocular signs correlate well with disease severity and genotype in Fabry disease. PLoS ONE. 2015;10:e0120814.CrossRef Pitz S, Kalkum G, Arash L, et al. Ocular signs correlate well with disease severity and genotype in Fabry disease. PLoS ONE. 2015;10:e0120814.CrossRef
13.
go back to reference Sodi A, Ioannidis AS, Mehta A, et al. Ocular manifestations of Fabry’s disease: data from the Fabry Outcome Survey. Br J Ophthalmol. 2007;91:210–4.CrossRef Sodi A, Ioannidis AS, Mehta A, et al. Ocular manifestations of Fabry’s disease: data from the Fabry Outcome Survey. Br J Ophthalmol. 2007;91:210–4.CrossRef
14.
go back to reference Atiskova Y, Rassuli R, Koehn AF, et al. Retinal hyperreflective foci in Fabry disease. Orphanet J Rare Dis. 2019;14:296.CrossRef Atiskova Y, Rassuli R, Koehn AF, et al. Retinal hyperreflective foci in Fabry disease. Orphanet J Rare Dis. 2019;14:296.CrossRef
15.
go back to reference Font RL, Fine BS. Ocular pathology in Fabry’s disease. Histochemical and electron microscopic observations. Am J Ophthalmol. 1972;73:419–30.CrossRef Font RL, Fine BS. Ocular pathology in Fabry’s disease. Histochemical and electron microscopic observations. Am J Ophthalmol. 1972;73:419–30.CrossRef
16.
go back to reference Sodi A, Germain DP, Bacherini D, et al. In vivo observation of retinal vascular deposits using adaptive optics imaging in Fabry disease. Retina. 2020;40:1623–9.CrossRef Sodi A, Germain DP, Bacherini D, et al. In vivo observation of retinal vascular deposits using adaptive optics imaging in Fabry disease. Retina. 2020;40:1623–9.CrossRef
17.
go back to reference Kylstra JA, Wierzbicki T, Wolbarsht ML, et al. The relationship between retinal vessel tortuosity, diameter, and transmural pressure. Graefes Arch Clin Exp Ophthalmol. 1986;224:477–80.CrossRef Kylstra JA, Wierzbicki T, Wolbarsht ML, et al. The relationship between retinal vessel tortuosity, diameter, and transmural pressure. Graefes Arch Clin Exp Ophthalmol. 1986;224:477–80.CrossRef
18.
go back to reference Sodi A, Guarducci M, Vauthier L, et al. Computer assisted evaluation of retinal vessels tortuosity in Fabry disease. Acta Ophthalmol. 2013;91:e113-119.CrossRef Sodi A, Guarducci M, Vauthier L, et al. Computer assisted evaluation of retinal vessels tortuosity in Fabry disease. Acta Ophthalmol. 2013;91:e113-119.CrossRef
19.
go back to reference Sodi A, Lenzetti C, Bacherini D, et al. Quantitative analysis of conjunctival and retinal vessels in Fabry disease. J Ophthalmol. 2019;2019:4696429.CrossRef Sodi A, Lenzetti C, Bacherini D, et al. Quantitative analysis of conjunctival and retinal vessels in Fabry disease. J Ophthalmol. 2019;2019:4696429.CrossRef
20.
go back to reference San Roman I, Rodriguez ME, Caporossi O, et al. Computer assisted retinal vessel tortuosity evaluation in novel mutation Fabry disease: towards new prognostic markers. Retina. 2017;37:592–603.CrossRef San Roman I, Rodriguez ME, Caporossi O, et al. Computer assisted retinal vessel tortuosity evaluation in novel mutation Fabry disease: towards new prognostic markers. Retina. 2017;37:592–603.CrossRef
21.
go back to reference Minnella AM, Barbano L, Verrecchia E, et al. Macular impairment in Fabry disease: a morpho-functional assessment by swept-source OCT angiography and focal electroretinography. Invest Ophthalmol Vis Sci. 2019;60:2667–75.CrossRef Minnella AM, Barbano L, Verrecchia E, et al. Macular impairment in Fabry disease: a morpho-functional assessment by swept-source OCT angiography and focal electroretinography. Invest Ophthalmol Vis Sci. 2019;60:2667–75.CrossRef
22.
go back to reference Cakmak AI, Atalay E, Cankurtaran V, et al. Optical coherence tomography angiography analysis of fabry disease. Int Ophthalmol. 2020;40:3023–32.CrossRef Cakmak AI, Atalay E, Cankurtaran V, et al. Optical coherence tomography angiography analysis of fabry disease. Int Ophthalmol. 2020;40:3023–32.CrossRef
23.
go back to reference Dogan C, Gonen B, Dincer MT, et al. Evaluation of the reasons for the microvascular changes in patients with Fabry disease using optic coherence tomography angiography. Eur J Ophthalmol. 2020; 1120672120974288 Dogan C, Gonen B, Dincer MT, et al. Evaluation of the reasons for the microvascular changes in patients with Fabry disease using optic coherence tomography angiography. Eur J Ophthalmol. 2020; 1120672120974288
24.
go back to reference Luyten LJ, Dockx Y, Madhloum N, et al. Association of retinal microvascular characteristics with short-term memory performance in children aged 4 to 5 years. JAMA Netw Open. 2020;3:e2011537.CrossRef Luyten LJ, Dockx Y, Madhloum N, et al. Association of retinal microvascular characteristics with short-term memory performance in children aged 4 to 5 years. JAMA Netw Open. 2020;3:e2011537.CrossRef
25.
go back to reference Nguyen TH, Bhuiyan A, Park L, Ramamohanarao K. An effective retinal blood vessel segmentation method using multi-scale line detection. Pattern Recogn. 2013;46:703–15.CrossRef Nguyen TH, Bhuiyan A, Park L, Ramamohanarao K. An effective retinal blood vessel segmentation method using multi-scale line detection. Pattern Recogn. 2013;46:703–15.CrossRef
26.
go back to reference Beck M. Demographics of FOS—the Fabry Outcome Survey. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006. Beck M. Demographics of FOS—the Fabry Outcome Survey. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006.
27.
go back to reference Lenders M, Brand E. FAbry STabilization indEX (FASTEX): Clinical evaluation of disease progression in Fabry patients. Mol Genet Metab. 2020;129:142–9.CrossRef Lenders M, Brand E. FAbry STabilization indEX (FASTEX): Clinical evaluation of disease progression in Fabry patients. Mol Genet Metab. 2020;129:142–9.CrossRef
28.
go back to reference Nowak A, Mechtler TP, Hornemann T, et al. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease. Mol Genet Metab. 2018;123:148–53.CrossRef Nowak A, Mechtler TP, Hornemann T, et al. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease. Mol Genet Metab. 2018;123:148–53.CrossRef
29.
go back to reference Niemann M, Rolfs A, Stork S, et al. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet. 2014;7:8–16.CrossRef Niemann M, Rolfs A, Stork S, et al. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet. 2014;7:8–16.CrossRef
30.
go back to reference Kiziltoprak H, Tekin K, Cevik S, et al. Normative data assessment of peripapillary and macular vessel density and foveal avascular zone metrics using optical coherence tomography angiography in children. J Pediatr Ophthalmol Strabismus. 2020;57:388–98.CrossRef Kiziltoprak H, Tekin K, Cevik S, et al. Normative data assessment of peripapillary and macular vessel density and foveal avascular zone metrics using optical coherence tomography angiography in children. J Pediatr Ophthalmol Strabismus. 2020;57:388–98.CrossRef
31.
go back to reference Goker YS, Kiziltoprak H, Tekin K, et al. Direct and crossover effects of Phenylephrine and Cyclopentolate on foveal avascular zone and vessel density of macular capillary plexuses: an optical coherence tomography angiography study. Rom J Ophthalmol. 2020;64:195–204.CrossRef Goker YS, Kiziltoprak H, Tekin K, et al. Direct and crossover effects of Phenylephrine and Cyclopentolate on foveal avascular zone and vessel density of macular capillary plexuses: an optical coherence tomography angiography study. Rom J Ophthalmol. 2020;64:195–204.CrossRef
32.
go back to reference Rabiolo A, Gelormini F, Marchese A, et al. Macular perfusion parameters in different angiocube sizes: does the size matter in quantitative optical coherence tomography angiography? Invest Ophthalmol Vis Sci. 2018;59:231–7.CrossRef Rabiolo A, Gelormini F, Marchese A, et al. Macular perfusion parameters in different angiocube sizes: does the size matter in quantitative optical coherence tomography angiography? Invest Ophthalmol Vis Sci. 2018;59:231–7.CrossRef
Metadata
Title
Retinal vessel tortuosity as a prognostic marker for disease severity in Fabry disease
Authors
Yevgeniya Atiskova
Jan Wildner
Martin Stephan Spitzer
Charlotte Aries
Nicole Muschol
Simon Dulz
Publication date
01-12-2021
Publisher
BioMed Central
Keyword
Fabry Disease
Published in
Orphanet Journal of Rare Diseases / Issue 1/2021
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-021-02080-0

Other articles of this Issue 1/2021

Orphanet Journal of Rare Diseases 1/2021 Go to the issue